– UK, Burton on Trent – Clinigen Group plc (LON:CLIN), the global pharmaceutical and services company, today announced that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.

Peter Allen, Chairman of Clinigen, said: “On behalf of the Board, we are delighted to welcome Alan to the Group. He brings extensive industry experience and expertise in pharmaceutical services. His appointment strengthens the Board and will help to support and deliver the Group’s strategy. We are very much looking forward to working with Alan in his new NED capacity.”

About Pr Alan Boyd

Alan is CEO of Boyd Consultants, a UK based consultancy to the pharmaceutical and biotechnology industry. He has over 30 years of sector experience, holding senior roles within Glaxo Group, ICI Pharma, Zeneca Pharmaceuticals and Ark Therapeutics. Alan is a graduate in Biochemistry and Medicine from the University of Birmingham and is currently a Fellow and immediate past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians. He is also a Fellow of the Royal College of Physicians, London and a Council Member of the Academy of Medical Royal Colleges.

Alan is currently working as a consultant for Clinigen providing clinical and regulatory consultancy services in relation to its medical products.

About Clinigen Group

Clinigen Group plc is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information : https://www.clinigengroup.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.